The study, published on Thursday in the journal Cell, offers a potential road map for making immunotherapy — a treatment that uses the body's own immune system to fight disease — more effective ...

Piper Sandler Virtual Novel Targets in Immunology Symposium February 12, 2026 5:00 PM ESTCompany ParticipantsPaul Burton - Senior VP ...

The trial’s primary end point was overall response rate (ORR). At the 3-year mark, the ORR was 59%, with a CR rate of 41%; both rates were maintained from prior analyses, “demonstrating the stability ...

Accessibility remains one of the largest barriers to translating academic best practices into a community oncology setting, according to several panelists at the Boston Regional Institute for ...

NovoCure secures FDA approval for Optune Pax in first-line locally advanced pancreatic cancer, first such approval in three decades. Read why NVCR is a Strong Buy.

The circumstances surrounding a study on a deadly virus could hardly have been more dramatic. One of its first authors was ...

New clinical trial data suggest vidofludimus calcium can target key mechanisms underlying progressive multiple sclerosis.

Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't ...

A lung cancer trial bolsters a long-held idea that treatment timing matters, showing a simple shift could help immunotherapy ...

In today’s issue: Our in-depth WP Intelligence report on Medicaid’s new approach to innovative yet pricey drugs. Botox ...

A shift toward personalized treatments and programmable cell therapies opens new doors for scientists engineering T cell-based treatments.

Colleen Mabasa, a patient with multiple myeloma, sat down with CURE for an interview to discuss how she pursued chimeric antigen receptor (CAR)-T cell therapy, navigated insurance and logistical ...